---
figid: PMC3511450__pone.0050085.g005
figtitle: Non Linear Programming (NLP) Formulation for Quantitative Modeling of Protein
  Signal Transduction Pathways
organisms:
- NA
pmcid: PMC3511450
filename: pone.0050085.g005.jpg
figlink: /pmc/articles/PMC3511450/figure/pone-0050085-g005/
number: F5
caption: (A) optimized pathway upon compartmentalization based on the equivalent classes
  concept (right panel). The proposed compartmentalization scheme groups together
  nodes that share identical in-silico responses under all experimental conditions,
  thus decreasing the parameters space. (B) Signaling dataset, consisting of 15 cytokines
  in combinations of two, and 3 inhibitors (including the no-inhibitor treatment),
  total of 120 experimental treatments (see ). The red background color corresponds
  to the measurement prediction mismatch of the solution.To generate model predictions
  the optimized values of all model parameters were used (i.e., parameter values obtained
  from the optimization procedure)
papertitle: Non Linear Programming (NLP) Formulation for Quantitative Modeling of
  Protein Signal Transduction Pathways.
reftext: Alexander Mitsos, et al. PLoS One. 2012;7(11):e50085.
year: '2012'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.7286987
figid_alias: PMC3511450__F5
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC3511450__F5
ndex: c8f65e31-de8f-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3511450__pone.0050085.g005.html
  '@type': Dataset
  description: (A) optimized pathway upon compartmentalization based on the equivalent
    classes concept (right panel). The proposed compartmentalization scheme groups
    together nodes that share identical in-silico responses under all experimental
    conditions, thus decreasing the parameters space. (B) Signaling dataset, consisting
    of 15 cytokines in combinations of two, and 3 inhibitors (including the no-inhibitor
    treatment), total of 120 experimental treatments (see ). The red background color
    corresponds to the measurement prediction mismatch of the solution.To generate
    model predictions the optimized values of all model parameters were used (i.e.,
    parameter values obtained from the optimization procedure)
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TGFA
  - EGF
  - BTC
  - NRG1
  - PDPK1
  - ITPR1
  - MTOR
  - DAG1
  - C1QA
  - C1QB
  - C1QC
  - C1R
  - C1S
  - PRKCD
  - PRKCG
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - PRKCZ
  - PRKCQ
  - PRKCI
  - PRKCH
  - CRK
  - CRKL
  - C2
  - DOCK1
  - BRAF
  - GAB1
  - PIGU
  - INPP5D
  - GRB2
  - INPPL1
  - JAK1
  - GAB2
  - MAP3K11
  - MAP3K10
  - JAK2
  - MAP3K15
  - MAP3K12
  - MAP3K13
  - MAP3K3
  - MAP3K4
  - MAP3K2
  - MAP3K8
  - MAP3K6
  - RAC1
  - RNASE1
  - MAP3K9
  - EGFR
  - RNU105B
  - ELSPBP1
  - IL1A
  - IL6
  - BBS9
  - IL1B
  - CRCP
  - CYTL1
  - TNF
  - KRAS
  - HRAS
  - NRAS
  - XYLT2
  - SOS1
  - SOS2
  - CAMK4
  - PRKCB
  - PRKCA
  - TRAF5
  - JAK3
  - CD40
  - C6
  - C5
  - CHUK
  - IKBKB
  - IKBKG
  - IKBKE
  - MAP2K6
  - MAP2K3
  - MAP2K4
  - MAP2K7
  - MAP3K5
  - MAP3K7
  - MAPK11
  - MAPKAPK2
  - MAPKAPK3
  - MAPKAPK5
  - RPS6KA4
  - RPS6KA5
  - MAP3K14
  - MAP4K4
  - TAB2
  - SRC
  - FGR
  - FYN
  - YES1
  - C7
  - TRAF6
  - ECSIT
  - C12orf57
  - SHC1
  - SHC2
  - SHC3
  - SHC4
  - ERBB2
  - ERBB3
  - AKR1C4
  - GZMB
  - POLR3K
  - ERBB4
  - MAP3K1
  - RAF1
  - RNASE3
  - MAP2K2
  - SUPT20H
  - TLR5
  - IL1R1
  - IL1R2
  - IL6ST
  - TIFA
  - IL22
  - IRAK1
  - MYD88
  - POLR3H
  - TRAF2
  - TANK
  - TNFRSF1B
  - RPS6KB1
  - IRS1
  - CREB1
  - CREB3
  - CREB5
  - CREB3L1
  - CREB3L2
  - CREB3L3
  - CREB3L4
  - CREM
  - ATF1
  - ATF2
  - MAPK1
  - MAPK3
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - HSPB1
  - HSPB2
  - MAP2K1
  - AKT1
  - AKT2
  - AKT3
  - EPHB2
  - RPS6KA1
  - STAT3
  - GSK3A
  - GSK3B
  - Cancer
  - Lung cancer
  - Noonan syndrome
  - Rheumatoid arthritis
---
